Skip to main content
Premium Trial:

Request an Annual Quote

Specialty Labs to Use Celera Genomic Data for Cirrhosis Test

NEW YORK, June 22 (GenomeWeb News) - Specialty Laboratories will use Celera Genomics' genetic data to develop a test to predict the risk for patients with hepatitis C virus of developing liver cirrhosis, the companies said today in a statement.

 

Specialty will pay Celera an upfront fee after it has validated a test, and it will pay Celera royalties on net sales in the United States, according to the statement. The companies did not disclose further financial details.

 

The companies believe a genetic test may be useful for a larger number of HCV-infected patients than currently used methods, Celera and Specialty said.

 

"Currently, there is an unmet medical need for a predictive method to determine which patients with chronic HCV are likely to develop fibrosis and progression to cirrhosis," said James Peter, founder and chairman of Specialty, in a statement.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.